Revenue grew 40% year-over-year to AUD 5.3 million, driven by HIV and Pascal OEM segments, with strong cash position and no debt. Operational upgrades and new product launches in syphilis and liver tests are expected to support continued growth into FY 2027.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.